The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Device and diagnostic valuations are still ... term growth concerns and mixed data for Novo’s next-generation drug CagriSema, leaving the door open for future challengers. Global GLP-1 Market ...

ResMed beats quarterly profit estimates on demand for sleep disorder devices Healthcare & Pharmaceuticalscategory ... next-generation obesity drug CagriSema on Feb. 10 to test its long-term ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity ...

While the initial market reaction to Novo's more enhanced CagriSema weight loss treatment ... One area we are excited about is medical devices, where portfolio holding Intuitive Surgical is ...

If approved, CagriSema will be the first fixed-dose combination ... comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health.

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment ... on a recent bearish report on Advanced Micro Devices Inc (NASDAQ:AMD) by Goldman Sachs.

Advanced Micro Devices Inc. (NASDAQ ... to be driven by the company’s next-gen obesity and diabetes drug, CagriSema, and by improvements in supply through organic growth as well as inorganically ...